Rectus Sheath Hematoma in a Patient with Dual-Antiplatelet Therapy Including Ticagrelor: A Case Report

Abstract

Rectus sheath hematoma (RSH) is an uncommon cause of abdominal pain associated with several risk factors including trauma, asthma, chronic obstructive pulmonary disease, pregnancy, and anticoagulation as it can be iatrogenic. Dual-antiplatelet therapy (DAPT), combined usage of a P₂Y₁₂ receptor inhibitor and aspirin, is a cornerstone treatment for patients with acute coronary syndromes. Ticagrelor is a P₂Y₁₂ receptor inhibitor with several adverse hemorrhagic complications. An 86-year-old male patient was admitted to the emergency department with abdominal pain and a palpable abdominal mass at the left upper quadrant of the abdomen. His medical history revealed coronary artery disease with medications including acetylsalicylic acid and ticagrelor. Contrast-enhanced abdominal computed tomography revealed RSH. The patient was treated conservatively with bed rest and analgesia. DAPT is an essential component of the management of acute coronary syndromes to prevent recurrent cardiac thrombotic events. However, hemorrhagic complications such as RSH may be encountered with DAPT. Emergency medicine physicians and cardiologists should keep in mind RSH in patients presenting with abdominal pain and using DAPT with ticagrelor.

Keywords

dual-antiplatelet therapy - hemorrhage - rectus abdominis - ticagrelor

Publication History

Received: 22 October 2022

Accepted: 25 January 2023

Article published online:
19 May 2023

• References

• 1 Valgimigli M, Bueno H, Byrne RA. et al; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
• 2 Becker RC, Bassand JP, Budaj A. et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32 (23) 2933-2944
• 3 Klingler PJ, Wetscher G, Glaser K, Tschmelitsch J, Schmid T, Hinder RA. The use of ultrasound to differentiate rectus sheath hematoma from other acute abdominal disorders. Surg Endosc 1999; 13 (11) 1129-1134
• 4 Hatjipetrou A, Anyfantakis D, Kastanakis M. Rectus sheath hematoma: a review of the literature. Int J Surg 2015; 13: 267-271
• 5 Salemis NS, Gourgiotis S, Karalis G. Diagnostic evaluation and management of patients with rectus sheath hematoma. A retrospective study. Int J Surg 2010; 8 (04) 290-293
• 6 Warren MH, Bhattacharya B, Maung AA, Davis KA. Contemporary management of spontaneous retroperitoneal and rectus sheath hematomas. Am J Surg 2020; 219 (04) 707-710
• 7 Aktürk OM, Kayılıoğlu SI, Aydoğan İ. et al. Spontaneous rectus sheath hematoma: an overview of 4-year single center experience. Indian J Surg 2015; 77 (Suppl. 03) 1219-1221
• 8 Sheth HS, Kumar R, DiNella J, Janov C, Kaldas H, Smith RE. Evaluation of risk factors for rectus sheath hematoma. Clin Appl Thromb Hemost 2016; 22 (03) 292-296
• 9 Salem N, Sharpe T, Singh A, Bhandari M. Formation of a rectus sheath hematoma secondary to COPD exacerbation while taking dual antiplatelet therapy. Cureus 2021; 13 (10) e18821
• 10 Feng C, Wang L, Wang L. Spontaneous hematoma in the setting of dual anti-platelet therapy with ticagrelor: a case report. Oncol Lett 2016; 12 (01) 144-146
• 11 Song YJ, Seol SH, Park J. et al. Hepatic subcapsular hematoma after dual antiplatelet therapy using ticagrelor. J Cardiovasc Dis Res 2020; 10 (04) 101-103
• 12 Go YI, Kim GW. Bilateral multifocal muscular hemorrhage in the triceps surae during antiplatelet therapy: a case report. J Int Med Res 2021; 49 (12) 3000605211064391